BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nivudirsen (BMN 351) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nivudirsen (BMN 351)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06280209-10782@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Nivudirsen (BMN 351): Phase 1/2 readout est. (NCT06280209)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 1/2\, Duchenne Muscular Dystrophy.
 \nStudy: A Phase 1/2 Study to Assess the Safety\, Tolerability\, Pharmacok
 inetics\, and Pharmacodynamics of BMN 351 in Participants With Duchenne Mu
 scular Dystrophy\nEstimated primary completion: 14 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06280209
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573631-10782@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nivudirsen (BMN 351): Phase 2 readout est. (NCT07573631)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 2\, Duchenne Muscular Dystrophy.\n
 Study: An Open-Label Extension Study to Evaluate the Long-term Safety and 
 Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy\nEsti
 mated primary completion: December 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07573631
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
